MPM BioVentures 2014, L.P.'s Form 4 filing
Werewolf Therapeutics, Inc. (HOWL) · filed Nov 20, 2025
- Accession no.
- 0001231919-25-000534
- Filed
- Nov 20, 2025, 5:51 PM ET
- Trade date
- Nov 18-20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $147.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| MPM BioVentures 2014, L.P.CIK 0001609492 | 10% Owner |
| MPM BioVentures 2014 (B), L.P.CIK 0001609493 | 10% Owner |
| MPM Asset Management Investors BV2014 LLCCIK 0001609495 | 10% Owner |
| MPM BioVentures 2014 LLCCIK 0001765021 | 10% Owner |
| MPM BioVentures 2014 GP LLCCIK 0001765091 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Common Stock | SSaleDisposed | −52,627 | $0.93F3 | −$48,943.11 | 5,428,912 | Indirect | Duplicate filing |
| Nov 19, 2025 | Common Stock | SSaleDisposed | −66,324 | $0.94F7 | −$62,344.56 | 5,362,588 | Indirect | Duplicate filing |
| Nov 20, 2025 | Common Stock | SSaleDisposed | −41,152 | $0.89F10 | −$36,625.28 | 5,321,436 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by Ansbert Gadicke.